National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov
In English | En español
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

nimotuzumab
A humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Nimotuzumab binds to and inhibits EGFR, resulting in growth inhibition of tumor cells that overexpress EGFR. This agent may act synergistically with radiation therapy. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:TheraCim hR3
Thera-CIM-hr3
Foreign brand name:Theraloc



Previous:Nilandron, nilotinib, nilutamide, nimodipine, Nimotop
Next:nimustine, Nipent, nitric oxide-releasing acetylsalicylic acid derivative, nitroglycerin, Nizoral

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov